Zydus Cadila has received an approval from the US FDA to market Risperidone Tablets 0.25, 0.05, 1, 2, 3, and 4 mg. Risperidone falls in the CNS segment and the estimated sales as per NDC was US$ 2.1 billion in 2007.
The group now has 41 approvals and has so far filed 79 ANDAs since the commencement of filing process in FY 2003-04.